Figure 3.

Combined CPMV and OX40 agonist treatment induces systemic antitumor effects in a CT26 colon tumor model. a) Schematic of the treatment strategy and dosing regimen. BALB/c mice were inoculated (i.p.) with 5 × 10⁵ CT26-luc cells followed by two weekly injections (i.p.) of 50 μg antibody (PD-1 antagonist or OX40 agonist), 50 μg CPMV, the combination, or PBS as a control (n = 5). b) IVIS images showing the growth of luc⁺ CT26 tumors in the different treatment groups. c) The average luciferase expression of tumor cells 17 dpi in the different treatment groups. Data are means ± SEM (n = 3–5). Statistical significance was calculated by one-way ANOVA: * versus PBS; *p < 0.05; ***p < 0.0005; ****p < 0.0001. d) Survival curves of the treatment groups. Statistical significance was calculated using a log-rank Mantel-Cox test: *p < 0.05, **p < 0.01. e) Schematic of the T cell depletion strategy using a CT26-luc colon tumor model. f) The average luciferase expression of tumor cells from different treatment groups in the T cell depletion study: PBS (blue), CPMV+OX40 agonist (red), CD4-specific antibody (100 μg, green), CD8-specific antibody (100 μg, purple). Data are means ± SEM (n = 4–5). g) Survival rate of each treatment group in the T cell depletion study. Statistical significance was calculated using a log-rank Mantel-Cox test: **p < 0.01.